**Table S1. Proportions of available data (%) at each visit.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Visit** | | |
| **Variable** | **Baseline (T0)** | **Follow-up 1 (T1)** | **Follow-up 2 (T2)** |
| No. group | 247 | 219 | 116 |
| Sex (%) | 100 | - | - |
| Age (%) | 99.6 | - | - |
| Diabetes duration (%) | 95.5 | - | - |
| Chronic kidney disease (%) | 100 | - | - |
| Previous cardiovascular event (%) | 100 | - | - |
| Previous treatment with basal insulin (%) | 100 |  |  |
| Previous basal insulin daily dose (%) | 77.7 | - | - |
| Previous basal insulin, type (%) | 81.8 | - | - |
| Degludec mean dose (%) | 100.0 | 100 | 99.1 |
| Treatment with short-acting insulin (%) | 75.3 | - | - |
| Short-acting insulin daily dose (%) | 66.4 | 71.2 | 75.9 |
| Short-acting insulin, type (%) | 75.3 | - | - |
| Premix insulin (%) | 100 | - | - |
| Glucose-lowering treatments (%) | 98.8 | - | - |
| HbA1c (%) | 95.1 | 89.0 | 90.5 |
| Body Mass Index (%) | 94.3 | - | - |
| Weight (%) | 96.8 | 93.6 | 96.6 |
| Fasting blood glucose (FBG) (%) | 90.7 | 88.6 | 89.7 |
| Post-prandial glucose (PPG) (%) | 40.9 | 42.9 | 42.2 |
| Standard deviation of mean blood glucose (%) | 40.1 | 44.3 | 45.7 |